EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia

Marta Dentoni, Irene Florean, Antonio Farina, Bastien Joubert, Le-Duy Do, Jérôme Honnorat, Valentina Damato, Martina Fabris, Gian Luigi Gigli, Mariarosaria Valente, Alberto Vogrig

The Cerebellum · 17.08.2024 · 23 (6) · 2308-2323

DOI: 10.1007/s12311-024-01727-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Cerebellum, online erschienen am 17.08.2024. Verfasst von Marta Dentoni und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Neurology, Department of Medicine (DMED), University of Udine, Udine, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Cerebellar Ataxia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Udine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abstract Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, and the association with immune-related adverse events (irAEs) is well-established. However, cerebellar irAEs are poorly defined and their relationship with paraneoplastic disorders remains unclear. Our aim was (i) to characterize cerebellar irAE; (ii) to compare it with paraneoplastic cerebellar ataxia (PCA). We performed a multicenter, retrospective, cohort study of patients developing new-onset, immune-mediated, isolated/predominant cerebellar dysfunction after ICI administration. In addition, a systematic review following PRISMA guidelines was performed. Cerebellar irAE cases were compared with a consecutive cohort of patients with PCA. Overall, 35 patients were included, of whom 12 were original cases (males: 25/35 (71%), median age: 65 [range: 20–82]). The most frequent tumor was non-small cell lung cancer (12/35, 34%). Anti-PD1 were adopted in 19/35 (54%). Symptoms developed at a median of 11 weeks after ICI onset. Neuronal antibodies were detected in 15/31 patients tested (48%). Cerebrospinal fluid was inflammatory in 25/30 (83%). Magnetic resonance imaging showed cerebellar hyperintensities in 8/35 (23%). Immunotherapy was applied in 33/35 cases (94%), and most patients improved with residual disability (16/35, 46%). When compared with a series of PCA ( n = 15), the cerebellar irAE group was significantly more associated with male sex, lung cancer (rather than gynecological/breast cancers), isolated ataxia, and a better outcome. We provide a detailed characterization of cerebellar irAE. Compared to PCA, differences exist in terms of tumor association, clinical features, and outcome. Clinical presentation-antibody-tumor triad in the ICI group only partially reflects the associations described in paraneoplastic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsCerebellar AtaxiaHumansMaleAgedFemaleMiddle AgedAged, 80 and overRetrospective StudiesAdultYoung AdultCohort StudiesNeoplasmsParaneoplastic Cerebellar Degeneration

Stichwörter der Autor:innen

Autoimmune encephalitisImmune-related adverse eventsNeurological adverse eventsNeurological toxicitiesParaneoplastic neurological syndromes

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Clinical Neurology, Department of Medicine (DMED), University of Udine, Udine, Italy.
  • Clinical Neurology, Department of Head-Neck and Neuroscience, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
  • French Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Lyon, France.
  • MeLiS - UCBL-CNRS UMR 5284 - INSERM U1314, Université Claude Bernard Lyon 1, Lyon, France.
  • Department of Neurosciences, Drugs and Child Health, University of Florence, Firenze, Italy.
  • Laboratory of Immunopathology, Institute of Clinical Pathology, Department of Laboratory Medicine, University Hospital of Udine, Udine, Italy.

Förderung

  • Università degli Studi di Udine

Zitieren

APA

Dentoni, M., Florean, I., Farina, A., Joubert, B., Do, L. D., Honnorat, J., Damato, V., Fabris, M., Gigli, G. L., Valente, M., & Vogrig, A. (2024). Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia. The Cerebellum, 23(6), 2308-2323. https://doi.org/10.1007/s12311-024-01727-5

Vancouver

Dentoni M, Florean I, Farina A, Joubert B, Do LD, Honnorat J, et al. Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia. The Cerebellum. 2024;23(6):2308-2323. doi:10.1007/s12311-024-01727-5

BibTeX
@article{Dentoni2024,
  author = {Dentoni, Marta and Florean, Irene and Farina, Antonio and Joubert, Bastien and Do, Le-Duy and Honnorat, Jérôme and Damato, Valentina and Fabris, Martina and Gigli, Gian Luigi and Valente, Mariarosaria and Vogrig, Alberto},
  title = {Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia},
  journal = {The Cerebellum},
  year = {2024},
  volume = {23},
  number = {6},
  pages = {2308--2323},
  doi = {10.1007/s12311-024-01727-5}
}
Kostenlos starten →